IOVANCE BIOTHERAPEUTICS, INC. IOVA

Latest FY: 2025 Healthcare Biotechnology
Market Price $8.71
Market Cap $3.89B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑60.6% YoY
$263.50M
Full year reported
Net Income ↓-5.1% YoY
-$390.98M
Net Margin: -148.4%
Free Cash Flow ↑7.6% YoY
-$336.24M
FCF Yield: -8.65%
EPS (Diluted) ↑14.8% YoY
$-1.09
Basic: $-1.09
Return on Equity Efficiency
-56.0%
ROA: -42.8%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (IOVA)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $-52.9M $-1.85 0.00% $-32.7M $-34.2M
FY 2017 $-92.1M -74.1% $-1.41 +23.8% 0.00% $-78.7M $-79.7M -133.2%
FY 2018 $-123.6M -34.2% $-1.27 +9.9% 0.00% $-101.2M $-102.4M -28.5%
FY 2019 $-197.6M -59.9% $-1.59 -25.2% 0.00% $-158.9M $-165.8M -61.8%
FY 2020 $-259.6M -31.4% $-1.88 -18.2% 0.00% $-205.1M $-251.9M -51.9%
FY 2021 $-342.3M -31.8% $-2.23 -18.6% 0.00% $-227.9M $-265.5M -5.4%
FY 2022 $-395.9M -15.7% $-2.49 -11.7% 0.00% $-292.8M $-313.2M -18.0%
FY 2023 $1.2M $-9.6M $-444.0M -12.2% $-1.89 +24.1% 0.00% $-361.8M $-384.1M -22.6%
FY 2024 $164.1M +13,699.0% $40.1M $-372.2M +16.2% $-1.28 +32.3% 0.00% $-353.0M $-364.0M +5.2%
FY 2025 $263.5M +60.6% $90.3M $-391.0M -5.1% $-1.09 +14.8% 0.00% $-302.4M $-336.2M +7.6%
$

Valuation

Market Price $8.71
Market Cap $3.89B
Enterprise Value $3.73B
P/E Ratio N/A
P/B Ratio 5.57
FCF Yield -8.65%
Dividend Yield N/A
Shares Outstanding 446,502,400
%

Profitability & Margins

Gross Margin 34.28%
Operating Margin -153.08%
Net Margin -148.38%
Return on Equity (ROE) -55.97%
Return on Assets (ROA) -42.82%
Asset Turnover 0.29x
Revenue 3-Yr CAGR N/A
🛡️

Financial Health & Liquidity

Current Ratio 3.20
Cash Ratio 1.18
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $163.08M
Total Debt N/A
Book Value / Share $1.56
💧

Cash Flow Efficiency

Operating Cash Flow -$302.41M
Capital Expenditures (CapEx) $33.84M
Free Cash Flow -$336.24M
OCF / Revenue -114.76%
FCF / Revenue -127.61%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-1.09
EPS (Basic) $-1.09
Dividends / Share N/A
Book Value / Share $1.56
EPS YoY Growth 14.84%
🏛️

Balance Sheet (FY 2025)

Total Assets $913.17M
Total Liabilities $214.59M
Stockholders' Equity $698.58M
Current Assets $442.69M
Current Liabilities $138.36M